# Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00005592** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 23 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** 90-Y-ibritumomab tiuxetan
- **BIOLOGICAL:** rituximab
- **RADIATION:** indium In 111 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00005592
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2002-03
- **Final completion:** 2005-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2015-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005592, "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00005592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*